PD11-02 ADVANCED PRACTICE PROVIDERS DELIVER EQUIVALENT OUTCOMES WITH INJECTION OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR PEYRONIE’S DISEASE

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD11-02 ADVANCED PRACTICE PROVIDERS DELIVER EQUIVALENT OUTCOMES WITH INJECTION OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR PEYRONIE’S DISEASE Reza Roshandel, Stephen Carlson, Elise Tentis, Kate Nelson, Eileen Byrne, Sevann Helo, Tobias S. Köhler, and Matthew J. Ziegelmann Reza RoshandelReza Roshandel More articles by this author , Stephen CarlsonStephen Carlson More articles by this author , Elise TentisElise Tentis More articles by this author , Kate NelsonKate Nelson More articles by this author , Eileen ByrneEileen Byrne More articles by this author , Sevann HeloSevann Helo More articles by this author , Tobias S. KöhlerTobias S. Köhler More articles by this author , and Matthew J. ZiegelmannMatthew J. Ziegelmann More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003251.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Independently performed procedures by well-trained advanced practice providers (APP) facilitate access to specialized care. We sought to compare outcomes between physicians and APPs with intralesional Collagenase Clostridium histolyticum (CCH). METHODS: Men receiving CCH between 2014-2021 at our institution by four physicians and four APPs were included in an IRB-approved database. CCH was delivered as a series of 8 injections per protocol. Patient demographics, procedural-related adverse events, and curvature changes were recorded. We describe an “APP-ratio”, defined as percentage of total injections administered by an APP per patient. RESULTS: After excluding patients who did not complete the entire CCH course and those who did not return for final assessment, 150/406 patients were analyzed. Mean baseline penile curvature was 66.2° (SD 23). Mean absolute and percent improvements in curvature were 21.7° (SD 18) and 33% (SD 27). The mean APP ratio was 69%, and 133 patients (89%) had at least 25% of their injections performed by an APP. There was no significant difference in absolute or relative curvature improvement based on the APP-ratio (Figure 1). The frequency of adverse events (pain, swelling, and hematoma). CONCLUSIONS: In our high-volume CCH practice, APPs achieve the same outcomes and safety compared to physicians. Greater training efforts expand access to care for patients with PD. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e332 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Reza Roshandel More articles by this author Stephen Carlson More articles by this author Elise Tentis More articles by this author Kate Nelson More articles by this author Eileen Byrne More articles by this author Sevann Helo More articles by this author Tobias S. Köhler More articles by this author Matthew J. Ziegelmann More articles by this author Expand All Advertisement PDF downloadLoading ...